drugset / Trial / NCT06519669

Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer

NCT06519669 ↗

Terminated 2 enrolled Grit Biotechnology
NaSingle-groupOpen-labelTreatment

Summary

This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) for treatment of patients with Advanced lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment.

Timeline

Start
2024-07-18
Primary completion
2025-12-30
Completion
2025-12-30

Outcome

Outcome not reported

Stopped (Business): “The study was terminated from a business perspective.”

Drugs

EvaluationDrugModalityDoseRoute
Subject GT201 Cell therapy — —

Indications